BCBeatriz Taveira Constantinou

Beatriz Taveira Constantinou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beatriz Taveira Constantinou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Use of pumpkin seed (Cucurbita pepo) versus placebo and versus alpha-blockers in the management of benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials

    by Bianca Caroline Benedicto, Beatriz Taveira Constantinou, Amauri Moreira Leite Junior, Soraya Hussein Orra, Beatriz Sanches Molina, Tayná Pereira Leite de Almeida, Beatriz Brandão da Silva Navas, Rodrigo Afonso da Silva Sardenberg, Fernando Gonçalves de Almeida, Ronaldo Soares Maia, et al.

    Purpose: To compare pumpkin seed (Cucurbita pepo) with placebo and, separately, with alpha-blockers in men with benign prostatic hyperplasia-related lower urinary tract symptoms. Methods: Five databases were searched to 30 April 2025 for randomized controlled trials (RCTs). The primary outcome was change in international prostate symptom score (IPSS), and secondary outcomes included maximum urinary flow (Qmax), prostate volume, prostate-specific antigen (PSA) and adverse events. Each comparator was analyzed separately by random-effects meta-analysis, with RoB 2 for risk of bias. Results: Eight RCTs (2,170 men) were included. Versus placebo, pumpkin seed reduced IPSS at three months (mean difference -0.62, 95% confidence interval [95%CI] -1.15 to -0.09) but not at six months; versus alpha-blockers there was no difference (1.91, IC95% -0.24–4.07). Qmax improved versus placebo only; no other outcome differed from alpha-blockers. Adverse events were fewer with pumpkin seed in one head-to-head trial (odds ratio = 0.21, IC95% 0.07–0.63). Conclusion: Pumpkin seed offers at most a small sub-clinical IPSS benefit over placebo, not maintained at six months, and no significant difference from alpha-blockers. Certainty was low to very low; equivalence is not established.

  • Open Access

    GreenLight photoselective laser vaporisation versus transurethral resection of the prostate for large prostates: systematic review and meta-analysis

    by Breno C. Porto, Bianca C. Benedicto, Beatriz T. Constantinou, Nathalie C. Hobaica, Carlo C. Passerotti, Richard Dobrucki de Lima, Rodrigo A. S. Sanderberg, Everson L. A. Artifon, Jose P. Otoch, Jose A. S. da Cruz

    Background: Transurethral resection of the prostate (TURP) stands as a primary surgical intervention for benign prostatic hyperplasia (BPH), although laser techniques, notably photoselective vaporisation of the prostate (PVP), are gaining traction. Previous studies have already assessed the efficacy of TURP and PVP, although with small prostates (Methods: A systematic review was conducted across MEDLINE, Embase, Scopus, Web of Science, and Google Scholar. Studies comparing PVP to TURP in male BPH patients were included. Our primary outcome was the International Prostate Symptom Score (IPSS). Secondary outcomes encompassed maximum urinary flow rate (Qmáx), postvoid residual volume (Vres), operative time, catheterization time, postoperative hospital stay and complications. To assess the risk of bias we used Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies, and risk of bias 2 tool (Cochrane) (RoB2) for the randomized. Results: Three articles encompassing 159 patients each in the PVP and TURP groups were included. Our analysis revealed no statistically significant difference in IPSS score between PVP and TURP [mean difference (MD) 1.56; 95% confidence interval (CI): 0.52 to 3.64; P=0.14; I2=85%]. TURP demonstrated a reduced operative time (MD 30.35; 95% CI: 11.26 to 49.44; P=0.002; I2=96%), whereas PVP exhibited shorter catheterization time (MD −2.22; 95% CI: −2.44 to −1.99; P2=1%) and postoperative hospital stay (MD −2.20; 95% CI: −2.69 to −1.72; P2=75%). No significant differences were observed in other outcomes assessed. Conclusions: This meta-analysis suggests that PVP is non-inferior to TURP concerning IPSS, Qmáx, Vres, and complications, albeit with a longer operative time. PVP showed a reduced catheterization and postoperative hospital stay.